Longboard Pharmaceuticals Inc logo

Longboard Pharmaceuticals Inc

San Diego, CA

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

longboardpharma.com

Company Details

Founded

2020

Employees

Between 50 - 100 employees

Raised

$1,596,968

Headquarters Location

San Diego, CA

Public

Yes

Acquired

Yes

CEO

Bassam Damaj

Founders

Bassam Damaj

Company Collections

These are collections Longboard Pharmaceuticals Inc is a part of. Click on the collection name to view similar companies.

Longboard Pharmaceuticals Inc's Industries

Longboard Pharmaceuticals Inc's Tech Stack